Navigation Links
Amylin Pharmaceuticals to Webcast Third Quarter Results
Date:10/13/2009

SAN DIEGO, Calif., Oct. 13, 2009 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) will webcast its Quarterly Update Conference Call for the third quarter of 2009 on Tuesday, October 20, 2009 at 5:00 p.m. ET/2:00 p.m. PT. Daniel M. Bradbury, Amylin's president and chief executive officer, will lead the call. On the same date post-market, Amylin will release financial results for the third quarter of 2009.

The call will be webcast live through Amylin's corporate Web site and a recording will be made available following the close of the call. To access the webcast, please log on to www.amylin.com approximately fifteen minutes prior to the call to register, download and install any necessary audio software. For those without access to the Internet, the live call may be accessed by phone by calling (866) 730-5763 (U.S./Canada) or (857) 350-1587 (international), conference access code 44746855. A replay of the call will also be available by phone beginning approximately two hours after the close of the call and can be accessed at (888) 286-8010 (U.S./Canada) or (617) 801-6888 (international), conference access code 78094555.

About Amylin

Amylin Pharmaceuticals is a biopharmaceutical company committed to improving lives through the discovery, development and commercialization of innovative medicines. Amylin has developed and gained approval for two first-in-class medicines for diabetes, SYMLIN® (pramlintide acetate) injection and BYETTA® (exenatide) injection. Amylin's research and development activities leverage the Company's expertise in metabolism to develop potential therapies to treat diabetes and obesity. Amylin is headquartered in San Diego, California. Further information on Amylin Pharmaceuticals is available at www.amylin.com.


'/>"/>
SOURCE Amylin Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Amylin and Lilly to Present More than 20 Studies for Exenatide at EASD 2009
2. Amylin Pharmaceuticals to Present at Morgan Stanley Global Healthcare Unplugged Conference
3. Amylin Pharmaceuticals Board of Directors Elects Paulo F. Costa Chairman of the Board
4. Amylin Pharmaceuticals to Webcast Second Quarter Results
5. Amylin Pharmaceuticals Announces Positive Results from Dose-Ranging Clinical Study of Pramlintide/Metreleptin Combination Treatment for Obesity
6. Amylin Pharmaceuticals to Present at Piper Jaffray Europe Conference
7. Amylin Pharmaceuticals to Present at Goldman Sachs Annual Global Health Care Conference
8. Amylin Announces Preliminary Tabulation of Annual Meeting Results
9. Amylin Responds to Eastbourne Letter
10. Amylin Comments on RiskMetrics Report
11. Amylin Pharmaceuticals to Present at Deutsche Bank Health Care Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/15/2014)... YORK & PETACH TIKVAH, Israel ... Inc. (NASDAQ: BCLI ), a leading developer ... today that wholly-owned subsidiary Brainstorm Cell Therapeutics Ltd. was ... Israel,s Office of the Chief Scientist ... been in receipt of grant support from the Office ...
(Date:12/13/2014)... N.C. (PRWEB) December 13, 2014 CanDiag, ... Charlotte) spin-out company has changed its name to OncoTab, ... accurate representation of where we are today,” said CEO ... extended our platform’s applications beyond breast cancer diagnostics to ... a reflection of that evolution.” , Founded in 2011 ...
(Date:12/13/2014)... The “Global Synthetic Biology Market (2013-2018)”, analyses and ... challenges. , The global synthetic biology market is ... Scientific, Inc. (U.S.), DuPont (U.S.), and Royal DSM ... ~65% of the total synthetic biology market. ... @ http://www.marketsandmarkets.com/Market-Reports/synthetic-biology-market-889.html , Thermo Fisher Scientific, ...
(Date:12/13/2014)... , Dec. 12, 2014  Vaccinex ... the discovery and development of therapeutic monoclonal ... today announced publication of a manuscript entitled ... inhibits remyelination in neurodegenerative disease" in the ... of Disease*.  The publication highlights an important ...
Breaking Biology Technology:BrainStorm Receives $1,100,000 for its 8th Annual Non-Dilutive Grant from Israel's Chief Scientist Office 2BrainStorm Receives $1,100,000 for its 8th Annual Non-Dilutive Grant from Israel's Chief Scientist Office 3CanDiag Inc. Expands Product Scope Under a New Name: OncoTab, Inc. 2Synthetic Biology Market to HIt $5.6304 Billion by 2018 - New Research Report by MarketsandMakets 2Synthetic Biology Market to HIt $5.6304 Billion by 2018 - New Research Report by MarketsandMakets 3Vaccinex announces publication of preclinical studies with an anti-SEMA4D antibody in animal models of neuroinflammatory and demyelinating disease 2
... March 18 Syndication Inc., (Pink Sheets: SYNJ), Reports ... of ,Director of Technical Engineering,. The job of the ... budget development of the Company,s Pinnacle Energy Division. The ... wind turbine energy, bio-diesel fuel production, and microwave plasma ...
... 11dhTxB2 to assess aspirin effectDENVER, March 18 ... worldwide developer and marketer of diagnostic test kits, ... Test March 29 - 31 at the American ... The annual meeting will take place in Orlando, ...
... Despite the initial regulatory hiccups, the number of ... increase gradually. The patent expiry of key biopharmaceuticals ... driving the development of biosimilars. In addition, payers, ... drugs due to their safety, efficacy and affordability, ...
Cached Biology Technology:Syndication Inc. Seeks 'DIRECTOR OF TECHNICAL ENGINEERING' for 'PINNACLE ENERGY' - Its New Alternative Energy Subsidiary 2Corgenix to Exhibit AspirinWorks(R) Test at ACC.09 2Corgenix to Exhibit AspirinWorks(R) Test at ACC.09 3The Need for Safe and Affordable Biopharmaceuticals Drives the Development of the European Biosimilars Market, Says Frost & Sullivan 2The Need for Safe and Affordable Biopharmaceuticals Drives the Development of the European Biosimilars Market, Says Frost & Sullivan 3The Need for Safe and Affordable Biopharmaceuticals Drives the Development of the European Biosimilars Market, Says Frost & Sullivan 4
(Date:12/15/2014)... DUBLIN , Dec. 12, 2014 Research ... announced the addition of the "Global Facial ... http://photos.prnewswire.com/prnh/20130307/600769 ... the identification of individuals. Facial recognition system measures ... as nose, jaw edges, mouth, and the distance ...
(Date:12/11/2014)... --Research and Markets , ... ) has announced the addition of the ... their offering. One major trend ... multimodal biometric systems. Multimodal biometric systems utilize more ... and identification purposes. This helps to reduce the ...
(Date:12/11/2014)... 10, 2014  Data Sciences International (DSI), the ... a new series of digital telemetry implants to ... M series, part of the PhysioTel™ Digital platform, ... possible physiologic data when incorporating functional endpoints into ... to toxicology studies has evolved from short ECG ...
Breaking Biology News(10 mins):Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 2Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 3Biometrics Market in India 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2New telemetry implants expected to change how large animal toxicology studies are conducted 2
... TX -- Researchers at Sam Houston State University and the ... from the criminal justice system in Houston to establish protocols ... by crime labs. , "This is a problem-solving project that ... tested," said Dr. William Wells, who is leading the research ...
... 2011 -- Experts agree that obesity prevention should begin before ... conclusive data, health care providers often have trouble advising parents ... study soon to be published in The Journal of ... may be an effective way to help prevent obesity. ...
... to deliver payloads of cancer-fighting drugs to tumors in ... treatment. But scientists are still at a relatively early ... Although developing nanoparticles that work as "magic bullets" ... is still the goal, the reality is that ...
Cached Biology News:Research to target untested rape kits 2Research to target untested rape kits 3Study suggests prolonged bottle feeding increases the risk of obesity 2Hitting target in cancer fight now easier with new nanoparticle platform, UCLA scientists say 2
... from Magnetofection technology, SilenceMag is the ... Simple, rapid and easy to use, ... toxic. Specifically designed for siRNA delivery, ... very low doses of siRNA.,SilenceMag formulation ...
... Cytological Labeling Kit provides a unique signal ... cellular targets, including cell-surface receptors and subcellular ... contains the patented ELF 97 phosphatase substrate, ... at the site of enzymatic activity ...
... Magnetofection technology, SilenceMag is the most ... rapid and easy to use, SilenceMag ... Specifically designed for siRNA delivery, SilenceMag ... low doses of siRNA.,SilenceMag formulation gives ...
... Radiochemical Purity is >95%NEN Radiolabeled Ligands\n\nReceptor-related ... continual availability of new radiolabeled ligands selected ... offers a wide range of products and ... including over 400 state-of-the-art radioligands. If you ...
Biology Products: